---
figid: PMC9333350__41416_2022_1876_Sch1_HTML
pmcid: PMC9333350
image_filename: 41416_2022_1876_Sch1_HTML.jpg
figure_link: /pmc/articles/PMC9333350/figure/Sch1/
number: Scheme 1
figure_title: The TLR9 signaling pathways
caption: The binding of CpG-ODN to TLR9 leads to the activation of type I IFN signaling
  pathway, NF-ÎºB signaling pathway and MAPK signaling pathway, which promotes the
  expression and release of pro-inflammatory cytokines in target cells.
article_title: 'Toll-like receptor 9 agonists and combination therapies: strategies
  to modulate the tumour immune microenvironment for systemic anti-tumour immunity.'
citation: Zhangchi Dongye, et al. Br J Cancer. 2022 Jul 28 ;127(9):1584-1594.
year: '2022'

doi: 10.1038/s41416-022-01876-6
journal_title: British Journal of Cancer
journal_nlm_ta: Br J Cancer
publisher_name: Nature Publishing Group UK

keywords:
- Drug development
- Cancer immunotherapy

---
